Graft Versus Host Disease Treatment Market: By Drug Class (Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors Others), By Disease Type (Acute Graft vs Host Disease, Chronic Graft vs Host Disease), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies Online Pharmacies) and By Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Graft Versus Host Disease Treatment Market size was valued at USD 2,967.9 million in 2022, growing at a CAGR of 8.1% during the forecast period 2023 to 2029.  By drug class, the global Graft vs Host Disease Treatment market has been segmented into Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors, Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of drug class. Based on Disease Type, the global Graft vs Host Disease Treatment market is segmented into Acute Graft vs Host Disease, Chronic Graft vs Host Disease. Among these, the Acute Graft vs Host Disease segment is expected to have the fastest-growing segment during the forecast period 2022-2028. Based on route of administration, the global Graft vs Host Disease Treatment market is segmented into Oral, Parenteral. The oral segment accounts for the largest share in 2021. Based on the distribution channel, the segment has been segregated into Hospital Pharmacies, Retail Pharmacies Online Pharmacies. The hospital pharmacies segment is expected to dominate other segments in the global market. The retail pharmacies segment is expected to witness the highest CAGR during the forecast period according to precision business insights.

Graft Versus Host Disease Treatment Market Key Developments:
  • In Sept 2021, Ruxolitinib has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic Graft-versus-Host disease in patients 12 years of age and older who have failed any two conventional therapies.
  • In May 2022, Jakavi ruxolitinib) from Novartis has been given European Commission (EC) approval for the treatment of patients with acute or chronic GvHD who have had a poor response to corticosteroids or other systemic treatments and are 12 years of age or older.

Graft Versus Host Disease Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific
Graft Versus Host Disease Treatment Market Dynamics

Rising count of the allogeneic hematopoietic stem cell transplant and increase in the prevalence of cancer patients are majorly driving the growth of graft versus host disease treatment market. The increasing bone marrow transplantations for various types of cancers is likely to drive the growth of the market. The growing R&D activities is helping in fastening up the drug development process which is expected to add fuel for the growth of the market. However, the higher investment in the initial stages of the clinical trials is likely to hamper the growth of the market. The strict government regulations for approvals is also hindering the growth of the graft versus host disease treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Graft Versus Host Disease Treatment Market Segmentation

By Product Type
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
  • Thalidomide
  • mTOR Inhibitors
  • Others
By Disease Type
  • Acute Graft vs. Host Disease (aGvHD)
  • Chronic Graft vs. Host disease (cGvHD)
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The Graft Versus Host Disease Treatment Market size was valued at USD 2,967.9 million in 2022

The Graft Versus Host Disease Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Asia Pacific is the fastest-growing for Graft Versus Host Disease Treatment Market

1. Executive Summary
2. Global Graft vs Host Disease Treatment Market Introduction
2.1. Global Graft vs Host Disease Treatment Market-Taxonomy
2.2. Global Graft vs Host Disease Treatment Market-Definitions
2.2.1. By Drug Class
2.2.2. By Disease Type
2.2.3. By Route of Administration
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Graft vs Host Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graft vs Host Disease Treatment Market Dynamic Factors - Impact Analysis
3.6. Global Graft vs Host Disease Treatment Market Competition Landscape
4. Global Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Graft vs Host Disease Treatment Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1. Monoclonal Antibodies
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunosuppressive Drugs
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Steroids
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. TNF Inhibitors
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Tyrosine Kinase Inhibitors
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Graft vs Host Disease Treatment Market, By Disease Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1. Acute Graft vs Host Disease
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Chronic Graft vs Host Disease
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Graft vs Host Disease Treatment Market, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1. Oral
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Graft vs Host Disease Treatment Market, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Graft vs Host Disease Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Region, 2023 - 2029
10. North America Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Monoclonal Antibodies
10.1.2. Immunosuppressive Drugs
10.1.3. Steroids
10.1.4. TNF Inhibitors
10.1.5. Tyrosine Kinase Inhibitors
10.1.6. Others
10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Acute Graft vs Host Disease
10.2.2. Chronic Graft vs Host Disease
10.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. USA
10.5.2. Canada
10.6. North America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
10.7. North America Graft vs Host Disease Treatment Market Dynamics Trends
11. Europe Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Monoclonal Antibodies
11.1.2. Immunosuppressive Drugs
11.1.3. Steroids
11.1.4. TNF Inhibitors
11.1.5. Tyrosine Kinase Inhibitors
11.1.6. Others
11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Acute Graft vs Host Disease
11.2.2. Chronic Graft vs Host Disease
11.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Rest of Europe
11.6. Europe Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
11.7. Europe Graft vs Host Disease Treatment Market Dynamics Trends
12. Asia-Pacific Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Monoclonal Antibodies
12.1.2. Immunosuppressive Drugs
12.1.3. Steroids
12.1.4. TNF Inhibitors
12.1.5. Tyrosine Kinase Inhibitors
12.1.6. Others
12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Acute Graft vs Host Disease
12.2.2. Chronic Graft vs Host Disease
12.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
12.7. Asia-Pacific Graft vs Host Disease Treatment Market Dynamics Trends
13. Latin America Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Monoclonal Antibodies
13.1.2. Immunosuppressive Drugs
13.1.3. Steroids
13.1.4. TNF Inhibitors
13.1.5. Tyrosine Kinase Inhibitors
13.1.6. Others
13.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Acute Graft vs Host Disease
13.2.2. Chronic Graft vs Host Disease
13.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
13.7. Latin America Graft vs Host Disease Treatment Market Dynamics Trends
14. Middle East and Africa Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
14.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Monoclonal Antibodies
14.1.2. Immunosuppressive Drugs
14.1.3. Steroids
14.1.4. TNF Inhibitors
14.1.5. Tyrosine Kinase Inhibitors
14.1.6. Others
14.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.2.1. Acute Graft vs Host Disease
14.2.2. Chronic Graft vs Host Disease
14.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. MEA Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
14.7. MEA Graft vs Host Disease Treatment Market Dynamics Trends
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. F. Hoffmann-La Roche Ltd.
15.2.2. AbbVie, Inc.
15.2.3. Bristol-Myers Squibb
15.2.4. Pfizer, Inc.
15.2.5. Baxter International plc
15.2.6. Novartis AG
15.2.7. Eli Lilly and Co.
15.2.8. Shire plc
15.2.9. Alleran plc
15.2.10. Caladrius
15.2.11. Eisai
15.2.12. Anterogen
16. Research Methodology
17. Key Assumptions and Acronyms
  • Novartis AG (Switzerland)
  • Merck & Co. (U.S)
  • Soligenix, Inc. (U.S)
  • Mesoblast Ltd (Australia)
  • Sanofi (France)
  • Neovii Biotech GmbH (Switzerland)
  • Astellas Pharma Inc. (Japan)
  • Mallinckrodt Pharmaceuticals (UK)

Adjacent Markets